Elafibranor: First Approval.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed.

1. Leveraging Advanced AI Frameworks for Dual PPAR α/γ Agonist Discovery in Alzheimer's Disease.ACS chemical neuroscience · 2026
   Review
2. Peroxisome Proliferator-Activated Receptor (PPAR) Agonists in Chronic Liver Diseases: Translating Mechanistic Insights into Clinical Practice and Future Perspectives.Cells · 2026
   Review
3. Targeted Metabolomics Uncovers NorCA's Role as a Potent Immunomodulator in Acute Pancreatitis by Promoting Macrophage Reprogramming and Efferocytosis.International journal of molecular sciences · 2026
   Article
4. Optimizing Care in Primary Biliary Cholangitis: Current Treatments and the Second-Line Decision.Digestive diseases and sciences · 2026
   Review
5. The Personalized Management of Primary Biliary Cholangitis in the Era of Precision Medicine: Current Challenges and Future Perspectives.Journal of personalized medicine · 2025
   Review
6. Primary Biliary Cholangitis: Immunopathogenesis and the Role of Bile Acid Metabolism in Disease Progression.International journal of molecular sciences · 2025
   Review
7. Emerging Therapeutics for Primary Biliary Cholangitis.The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2025
   Review
8. Polypharmacology: new drugs in 2023-2024.Pharmacological reports : PR · 2025
   Review
9. Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024.Pharmaceuticals (Basel, Switzerland) · 2025
   Review
10. A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2024.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Review
11. Compound 3d Attenuates Metabolic Dysfunction-Associated Steatohepatitis via Peroxisome Proliferator-Activated Receptor Pathway Activation and Inhibition of Inflammatory and Apoptotic Signaling.Metabolites · 2025
    Article
12. A Comprehensive Review of Metabolic Dysfunction-Associated Steatotic Liver Disease: Its Mechanistic Development Focusing on Methylglyoxal and Counterbalancing Treatment Strategies.International journal of molecular sciences · 2025
    Review
13. Prospects of elafibranor in treating alcohol-associated liver diseases.World journal of gastroenterology · 2025
    Article
14. Mechanism-guided drug development and treatment for liver fibrosis: a clinical perspective.Frontiers in pharmacology · 2025
    Review

Corrections and comments

• Erratum issued
  Correction: Elafibranor: First Approval.2024

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as